Core Viewpoint - 华检医疗's stock has surged over 200% in the past four weeks, reflecting strong market interest and investor confidence following a strategic partnership announcement [1] Group 1: Stock Performance - 华检医疗's stock price increased by 9% during trading, reaching 6.17 HKD, with a trading volume of 23.32 million HKD [1] - The cumulative increase over the last four weeks has exceeded 200% [1] Group 2: Strategic Partnership - On July 30, 华检医疗 announced a strategic cooperation framework agreement with 华大共赢 to establish the "华检华大共赢创新药知识产权代币化基金" [1] - The fund will invest in 华检医疗's "NewCo+RWA" Web3 exchange ecosystem projects in Hong Kong, the United States, and other locations [1] Group 3: Industry Innovation - The "IVDNewCo Exchange" aims to address significant pain points in the pharmaceutical industry, where new drug development takes about 10 years, with 80% of funding spent in clinical stages [1] - 华检医疗's solution involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital tokens using RWA technology [1] - The goal is to become a "Nasdaq + Uniswap" in the medical RWA field, ensuring compliance while achieving decentralized liquidity [1]
港股异动｜华检医疗(01931)盘中再涨9% 近四周累涨200% 携手华大共赢建立创新药RWA专属基金